Several studies have shown that inhibition of IL-6 enhances the therapeutic efficacy of α-PD-L1 therapy in melanoma, colorectal cancer, pancreatic cancer and hepatocellular carcinoma 45-48. The gene discussed is IL6; the disease is hepatocellular carcinoma.